MAPT and Alzheimer disease: A decrease in IGF-I levels in AD and VD has been widely documented and it may be involved in the development of neurofibrillary tangles, abnormal amyloid β metabolism and aberrant Tau phosphorylation, cognitive loss, neural inflammation, oxidative stress or mitochondrial dysfunction, among others[68,325].